O	0	7	Effects
O	8	10	of
O	11	21	ultrasound
O	21	22	-
O	22	28	guided
B-intervention	29	37	stellate
I-intervention	37	38	-
I-intervention	38	46	ganglion
I-intervention	47	52	block
O	53	55	on
B-condition	56	61	sleep
I-condition	62	65	and
I-condition	66	74	regional
I-condition	75	83	cerebral
I-condition	84	90	oxygen
I-condition	91	101	saturation
O	102	104	in
O	105	113	patients
O	114	124	undergoing
O	125	131	breast
O	132	138	cancer
O	139	146	surgery
O	146	147	:
O	148	149	a
O	150	160	randomized
O	160	161	,
O	162	172	controlled
O	172	173	,
O	174	180	double
O	180	181	-
O	181	188	blinded
O	189	194	trial
O	194	195	.

O	196	204	Numerous
O	205	212	factors
O	213	218	could
O	219	229	contribute
O	230	232	to
O	233	238	sleep
O	239	251	disturbances
O	252	254	in
O	255	260	women
O	261	265	with
O	266	272	breast
O	273	279	cancer
O	279	280	.

O	281	283	We
O	284	296	hypothesized
O	297	301	that
O	302	310	stellate
O	311	319	ganglion
O	320	325	block
O	326	327	(
O	327	330	SGB
O	330	331	)
O	332	338	during
O	339	346	surgery
O	347	352	would
O	353	361	preserve
O	362	367	sleep
O	368	373	after
O	374	381	surgery
O	382	385	and
O	386	394	increase
O	395	409	intraoperative
O	410	418	regional
O	419	427	cerebral
O	428	434	oxygen
O	435	445	saturation
O	446	447	(
O	447	451	rSO2
O	451	452	)
O	453	455	on
O	456	459	the
O	460	467	blocked
O	468	472	side
O	473	475	in
O	476	484	patients
O	485	495	undergoing
O	496	502	breast
O	503	509	cancer
O	510	517	surgery
O	517	518	.

O	519	520	A
O	521	531	randomized
O	531	532	,
O	533	539	double
O	539	540	-
O	540	547	blinded
O	547	548	,
O	549	559	controlled
O	560	565	trial
O	566	569	was
O	570	579	conducted
O	580	582	at
O	583	586	the
O	587	592	First
O	593	601	Hospital
O	602	604	of
O	605	610	China
O	611	618	Medical
O	619	629	University
O	630	634	from
O	635	642	January
O	643	647	2016
O	648	650	to
O	651	660	September
O	661	665	2016
O	665	666	.

B-total-participants	667	673	Ninety
I-total-participants	673	674	-
I-total-participants	674	677	six
B-eligibility	678	686	patients
I-eligibility	687	690	who
I-eligibility	691	700	underwent
I-eligibility	701	708	radical
I-eligibility	709	715	breast
I-eligibility	716	722	cancer
I-eligibility	723	730	surgery
I-eligibility	731	740	requiring
I-eligibility	741	748	general
I-eligibility	749	760	anaesthesia
O	761	765	were
O	766	774	randomly
O	775	783	assigned
O	784	786	to
O	787	790	one
O	791	793	of
O	794	797	two
O	798	803	study
O	804	810	groups
O	810	811	:
O	812	813	a
B-control	814	821	control
I-control	822	827	group
O	828	832	that
O	833	841	received
O	842	843	a
O	844	850	saline
O	851	854	SGB
O	855	858	and
O	859	860	a
O	861	866	block
O	867	872	group
O	873	877	that
O	878	886	received
O	887	888	a
O	889	890	0
O	890	891	.
O	891	893	25
O	893	894	%
O	895	906	ropivacaine
O	907	920	hydrochloride
O	921	924	SGB
O	924	925	.

O	926	929	The
O	930	937	primary
O	938	945	outcome
O	946	953	measure
O	954	957	was
O	958	961	the
B-outcome-Measure	962	975	postoperative
I-outcome-Measure	976	981	sleep
I-outcome-Measure	982	989	profile
O	989	990	,
O	991	996	which
O	997	1000	was
O	1001	1009	assessed
O	1010	1015	using
O	1016	1019	the
O	1020	1030	bispectral
O	1031	1036	index
O	1037	1039	on
O	1040	1043	the
O	1044	1049	first
O	1050	1063	postoperative
O	1064	1069	night
O	1069	1070	.

O	1071	1074	The
O	1075	1084	secondary
O	1085	1092	outcome
O	1093	1100	measure
O	1101	1104	was
O	1105	1108	the
B-outcome-Measure	1109	1123	intraoperative
I-outcome-Measure	1124	1128	rSO2
O	1128	1129	,
O	1130	1139	monitored
O	1140	1143	was
O	1144	1154	throughout
O	1155	1162	surgery
O	1163	1168	using
O	1169	1173	near
O	1173	1174	-
O	1174	1182	infrared
O	1183	1195	spectroscopy
O	1195	1196	.

O	1197	1198	A
O	1199	1204	total
O	1205	1207	of
B-total-participants	1208	1210	91
O	1211	1217	female
O	1218	1226	patients
O	1227	1228	(
O	1228	1232	mean
O	1233	1236	age
O	1236	1237	:
B-age	1238	1240	45
I-age	1241	1246	years
I-age	1246	1247	;
I-age	1248	1253	range
I-age	1254	1256	24
I-age	1256	1257	-
I-age	1257	1259	51
I-age	1260	1265	years
O	1265	1266	)
O	1267	1271	were
O	1272	1280	included
O	1281	1283	in
O	1284	1287	the
O	1288	1293	study
O	1293	1294	.

O	1295	1298	The
B-outcome	1299	1307	duration
I-outcome	1308	1310	of
I-outcome	1311	1316	sleep
O	1317	1320	was
O	1321	1334	significantly
O	1335	1344	increased
O	1345	1347	by
O	1348	1350	66
O	1350	1351	.
O	1351	1352	3
O	1353	1356	min
O	1357	1359	in
O	1360	1363	the
O	1364	1375	ropivacaine
O	1375	1376	-
O	1376	1379	SGB
O	1380	1385	group
O	1386	1394	compared
O	1395	1399	with
O	1400	1403	the
O	1404	1410	saline
O	1410	1411	-
O	1411	1414	SGB
O	1415	1420	group
O	1420	1421	.

O	1422	1424	No
O	1425	1436	differences
O	1437	1439	in
B-outcome	1440	1444	rSO2
O	1445	1449	were
O	1450	1458	observed
O	1459	1461	on
O	1462	1468	either
O	1469	1472	the
O	1473	1477	left
O	1478	1480	or
O	1481	1486	right
O	1487	1491	side
O	1492	1494	of
O	1495	1498	the
O	1499	1507	patients
O	1508	1510	in
O	1511	1517	either
O	1518	1523	group
O	1524	1526	50
O	1527	1530	min
O	1531	1536	after
O	1537	1548	anaesthesia
O	1549	1558	induction
O	1558	1559	.

O	1560	1562	We
O	1563	1571	conclude
O	1572	1576	that
O	1577	1588	ropivacaine
O	1588	1589	-
O	1589	1592	SGB
O	1593	1601	combined
O	1602	1606	with
O	1607	1614	general
O	1615	1626	anaesthesia
O	1627	1632	might
O	1633	1641	increase
O	1642	1645	the
O	1646	1651	first
O	1652	1665	postoperative
O	1666	1671	sleep
O	1672	1680	duration
O	1681	1688	without
O	1689	1700	influencing
O	1701	1704	the
O	1705	1719	intraoperative
O	1720	1724	rSO2
O	1725	1727	in
O	1728	1734	female
O	1735	1743	patients
O	1744	1754	undergoing
O	1755	1763	elective
O	1764	1770	breast
O	1771	1777	cancer
O	1778	1785	surgery
O	1785	1786	.

O	1787	1795	Clinical
O	1796	1802	trials
O	1802	1803	.
O	1803	1806	gov
O	1807	1817	identifier
O	1818	1829	NCT02651519
O	1829	1830	.
